SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...
Clinical trials have used various doses and treatment ... The dose administered to patients with CLL in the phase 3 trial was 100 mg/m 2 daily on 2 consecutive days every 28 days ( Table 1).
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
Researchers at Dana-Farber Cancer Institute are presenting a promising advance in the treatment of chronic lymphocytic ...
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
Grandad William Bennett, 69, was diagnosed with chronic lymphocytic leukaemia (CLL) 12 years ago, a type of blood cancer ...